**WHAT IS CLAIMED IS:**

1. A multi-specific antibody or an antigen-binding fragment thereof, comprising a first binding domain and a second binding domain, wherein the first binding domain specifically binds to CD276 and the second binding domain specifically binds to a second target other than CD276,

   wherein

   the first binding domain comprises a heavy chain variable region selected from the group consisting of:

   a) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 1-3;
   b) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 9-11;
   c) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 17-19;
   d) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 25-27;
   e) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 33-35;
   f) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 41-43;
   g) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 49-51;
   h) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 57-59;
   i) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 65-67;
   j) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 73-75;

k) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 81-83;

l) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 89-91;

m) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 97-99;

n) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 105-107;

o) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 113-115;

p) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 121-123;

q) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 129-131;

r) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 137-139;

s) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 145-147;

t) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 153-155;

u) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 161-163;

v) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 169-171;

w) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 177-179;

x) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 185-187;

y) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 193-195;

z) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 201-203;

aa) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 209-211;

bb) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 217-219;

cc) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 225-227;

dd) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 233-235;

ee) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 241-243;

ff) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 249-251;

gg) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 257-259;

hh) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 265-267;

ii) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 273-275;

jj) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 281-283;

kk) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 289-291;

ll) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 297-299;

mm) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 305-307;

nn) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 313-315;

oo) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 321-323;

pp) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 329-331;

qq) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 337-339; and

rr) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 9, 374 and 375,

and/or

the first binding domain comprises a light chain variable region selected from the group consisting of:

a) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 4-6;

b) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 12-14;

c) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 20-22;

d) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 28-30;

e) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 36-38;

f) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 44-46;

g) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 52-54;

h) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 60-62;

i) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 68-70;

j) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 76-78;

k) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 84-86;

l) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 92-94;

m) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 100-102

n) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 108-110;

o) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 116-118;

p) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 124-126;

q) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 132-134;

r) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 140-142;

s) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 148-150;

t) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 156-158;

u) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 164-166;

v) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 172-174;

w) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 180-181;

x) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 188-190;

y) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 196-198;

z) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 204-206;

aa) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 212-214;

bb) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 220-222;

cc) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 228-230;

dd) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 236-238;

ee) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 244-246;

ff) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 252-254;

gg) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 260-262;

hh) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 268-270, ;

ii) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 276-278;

jj_ a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 284-286;

kk) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 292-294;

ll) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 300-302;

mm) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 308-310;

nn) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 316-318;

oo) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 324-326;

pp) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 332-334;

qq) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 340-342;

rr) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 376, 13 and 14; and

ss) a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NOs: 377, 45 and 46.

2. The multi-specific antibody or antigen-binding fragment thereof of claim 1, wherein the first binding domain comprises:

a) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6;

b) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14;

c) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22;

d) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27; and a light

chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30;

e) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38;

f) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:41, SEQ ID NO: 42, and SEQ ID NO: 43; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 44, SEQ ID NO: 45, and SEQ ID NO:46;

g) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:49, SEQ ID NO: 50, and SEQ ID NO: 51; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54;

h) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID SEQ ID NO: 60, SEQ ID NO: 61, and SEQ ID NO: 62;

i) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 65, SEQ ID NO: 66, and SEQ ID NO: 67; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70;

j) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 73, SEQ ID NO: 74, and SEQ ID NO: 75; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 76, SEQ ID NO: 77, and SEQ ID NO: 78;

k) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 81, SEQ ID NO: 82, and SEQ ID NO: 83; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 84, SEQ ID NO: 85, and SEQ ID NO: 86;

l) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 89, SEQ ID NO: 90, and SEQ ID NO: 91; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 92, SEQ ID NO: 93, and SEQ ID NO: 94;

m) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 97, SEQ ID NO: 98, and SEQ ID NO: 99; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 100, SEQ ID NO: 101, and SEQ ID NO: 102;

n) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 105, SEQ ID NO: 106, and SEQ ID NO: 107; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 108, SEQ ID NO: 109 and SEQ ID NO: 110;

o) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 113, SEQ ID NO: 114, and SEQ ID NO: 115; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 116, SEQ ID NO: 117, and SEQ ID NO: 118;

p) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 121, SEQ ID NO: 122, and SEQ ID NO: 123; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 126;

q) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:129, SEQ ID NO: 130, and SEQ ID NO: 131; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 132, SEQ ID NO: 133, and SEQ ID NO:134;

r) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:137, SEQ ID NO: 138, and SEQ ID NO: 139; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 140, SEQ ID NO: 141, and SEQ ID NO: 142;

s) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 145, SEQ ID NO: 146, and SEQ ID NO: 147; and a light

chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150;

t) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 153, SEQ ID NO: 154, and SEQ ID NO: 155; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 156, SEQ ID NO: 157, and SEQ ID NO: 158;

u) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 161, SEQ ID NO: 162, and SEQ ID NO: 163; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 164, SEQ ID NO: 165, and SEQ ID NO: 166;

v) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 169, SEQ ID NO: 170, and SEQ ID NO: 171; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 172, SEQ ID NO: 173, and SEQ ID NO: 174;

w) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 177, SEQ ID NO: 178, and SEQ ID NO: 179; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 180, SEQ ID NO: 181, and SEQ ID NO: 182;

x) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 185, SEQ ID NO: 186, and SEQ ID NO: 187; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 188, SEQ ID NO: 189, and SEQ ID NO: 190;

y) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 193, SEQ ID NO: 194, and SEQ ID NO: 195; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 196, SEQ ID NO: 197 and SEQ ID NO: 198;

z) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 201, SEQ ID NO: 202, and SEQ ID NO: 203; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 204, SEQ ID NO: 205, and SEQ ID NO: 206;

aa) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 209, SEQ ID NO: 210, and SEQ ID NO: 211; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 212, SEQ ID NO: 213, and SEQ ID NO: 214;

bb) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:217, SEQ ID NO: 218, and SEQ ID NO: 219; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 220, SEQ ID NO: 221, and SEQ ID NO:222;

cc) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:225, SEQ ID NO: 226, and SEQ ID NO: 227; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 228, SEQ ID NO: 229, and SEQ ID NO: 230;

dd) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 233, SEQ ID NO: 234, and SEQ ID NO: 235; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID SEQ ID NO: 236, SEQ ID NO: 237, and SEQ ID NO: 238;

ee) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 241, SEQ ID NO: 242, and SEQ ID NO: 243; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 244, SEQ ID NO: 245, and SEQ ID NO: 246;

ff) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 249, SEQ ID NO: 250, and SEQ ID NO: 251; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 252, SEQ ID NO: 253, and SEQ ID NO: 254;

gg) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 257, SEQ ID NO: 258, and SEQ ID NO: 259; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 260, SEQ ID NO: 261, and SEQ ID NO: 262;

hh) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 265, SEQ ID NO: 266, and SEQ ID NO: 267; and a light

chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 268, SEQ ID NO: 269, and SEQ ID NO: 270;

ii) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 273, SEQ ID NO: 274, and SEQ ID NO: 275; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 276, SEQ ID NO: 277, and SEQ ID NO: 278;

jj) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 281, SEQ ID NO: 282, and SEQ ID NO: 283; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 284, SEQ ID NO: 285 and SEQ ID NO: 286;

kk) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 289, SEQ ID NO: 290, and SEQ ID NO: 291; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 292, SEQ ID NO: 293, and SEQ ID NO: 294;

ll) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 297, SEQ ID NO: 298, and SEQ ID NO: 299; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 300, SEQ ID NO: 301, and SEQ ID NO: 302;

mm) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:305, SEQ ID NO: 306, and SEQ ID NO: 307; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 308, SEQ ID NO: 309, and SEQ ID NO:310;

nn) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO:313, SEQ ID NO: 314, and SEQ ID NO: 315; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 316, SEQ ID NO: 317, and SEQ ID NO: 318;

oo) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 321, SEQ ID NO: 322, and SEQ ID NO: 323; and a light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID SEQ ID NO: 324, SEQ ID NO: 325, and SEQ ID NO: 326;

pp) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 329, SEQ ID NO: 330, and SEQ ID NO: 331; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 332, SEQ ID NO: 333, and SEQ ID NO: 334;

qq) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 337, SEQ ID NO: 338, and SEQ ID NO: 339; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 340, SEQ ID NO: 341, and SEQ ID NO: 342;

rr) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 9, SEQ ID NO: 374, and SEQ ID NO: 375; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 376, SEQ ID NO: 13, and SEQ ID NO: 14; or

ss) a heavy chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences selected from SEQ ID NO: 377, SEQ ID NO: 45, and SEQ ID NO: 46.

3. The multi-specific antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the first binding domain comprises a heavy chain variable region selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 31, SEQ ID NO: 39, SEQ ID NO: 47, SEQ ID NO: 55, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 79, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 103, SEQ ID NO: 111, SEQ ID NO: 119, SEQ ID NO: 127, SEQ ID NO: 135, SEQ ID NO: 143, SEQ ID NO: 151, SEQ ID NO: 159, SEQ ID NO: 167, SEQ ID NO: 175, SEQ ID NO: 183, SEQ ID NO: 191, SEQ ID NO: 199, SEQ ID NO: 207, SEQ ID NO: 215, SEQ ID NO: 223, SEQ ID NO: 231, SEQ ID NO: 239, SEQ ID NO: 247, SEQ ID NO: 255, SEQ ID NO: 263, SEQ ID NO: 271, SEQ ID NO: 279, SEQ ID NO: 287, SEQ ID NO: 295, SEQ ID NO: 303, SEQ ID NO: 311, SEQ ID NO: 319, SEQ ID NO: 327, SEQ

ID NO: 335, SEQ ID NO: 343, SEQ ID NO: 347, and SEQ ID NO: 349 and the homologue sequences of at least 80% sequence identity thereof;

and/or

the first binding domain comprises a light chain variable region selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 24, SEQ ID NO: 32, SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 56, SEQ ID NO: 64, SEQ ID NO: 72, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 104, SEQ ID NO: 112, SEQ ID NO: 120, SEQ ID NO: 128, SEQ ID NO: 136, SEQ ID NO: 144, SEQ ID NO: 152, SEQ ID NO: 160, SEQ ID NO: 168, SEQ ID NO: 1756, SEQ ID NO: 184, SEQ ID NO: 192, SEQ ID NO: 200, SEQ ID NO: 208, SEQ ID NO: 216, SEQ ID NO: 224, SEQ ID NO: 232, SEQ ID NO: 240, SEQ ID NO: 248, SEQ ID NO: 256, SEQ ID NO: 264, SEQ ID NO: 272, SEQ ID NO: 280, SEQ ID NO: 288, SEQ ID NO: 296, SEQ ID NO: 304, SEQ ID NO: 312, SEQ ID NO: 320, SEQ ID NO: 328, SEQ ID NO: 336, SEQ ID NO: 344, SEQ ID NO: 348, and SEQ ID NO: 350 and the homologue sequences of at least 80% sequence identity thereof.

4. The multi-specific antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the first binding domain comprises SEQ ID NO: 378 (EVQLVESGGGLXQPGXSLRLSCXTSGFTLSDYYMSWVRQXPGKGLEWV XFMRNKANXYTTEYSASVRGRFTISRDTSKSXIYLQMNSLXXEDTAVYY CVRDRXGRPFAYWGQGTLVTVSS), wherein the X at position i (i=12, 16, 23, 40, 49, 57, 80, 89, 90 and 103) of SEQ ID NO: 378 is referred as $X_{Hi}$, wherein $X_{H12}$ is V or I, $X_{H16}$ is G or R, $X_{H23}$ is A or T, $X_{H40}$ is A or P, $X_{H49}$ is G or S, $X_{H57}$ is A or G, $X_{H80}$ is I or T, $X_{H89}$ is R or K, $X_{H90}$ is A or T, $X_{H103}$ is D or E; and

a light chain variable region comprising SEQ ID NO: 379 (DIXMTQSPXSLXXXXGXXXXIXCKSSQSLLNXINQKNFLTWYXQKPGX XPXLLIYWASTRESGVPXRFSGSGSGTDFTLXISXXXXEDLXXYYCQNDY TYPLTFGQGTKLEIK), wherein the X at position i (i=3, 9, 12, 13, 14, 15, 17, 18, 19, 20, 22, 32, 43, 48, 49, 51, 66, 80, 83, 84, 85, 86, 90 and 91) of SEQ ID NO:

379 is referred as $X_{Li}$, wherein $X_{L3}$ is V or Q, $X_{L9}$ is D, L or S, $X_{L12}$ is A, S or P, $X_{L13}$ is A or V, $X_{L14}$ is S or T, $X_{L15}$ is L, V or P, $X_{L17}$ is D or E, $X_{L18}$ is R or P, $X_{L19}$ is A or V, $X_{L20}$ is S or T, $X_{L22}$ is N, T or S, $X_{L32}$ is A or S, $X_{L43}$ is Q or L, $X_{L48}$ is Q or K, $X_{L49}$ is A, P or S, $X_{L51}$ is K or Q, $X_{L66}$ is S or D, $X_{L80}$ is K or T, $X_{L83}$ is R or S, $X_{L84}$ is L or V, $X_{L85}$ is Q or E, $X_{L86}$ is A or P, $X_{L90}$ is A or G, $X_{L91}$ is T or V.

5. The multi-specific antibody or antigen-binding fragment thereof of claim 4, wherein the first binding domain comprises a heavy chain variable region comprising SEQ ID NO: 380 (QVQLQESGPGLVKPSXTLSLTCXVXGYSITSDYAWNWIRQXPGKGLEWI GYISHSGSTSYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARSL GRRWYFDVWGQGTTVTVSS), wherein the X at position i (i=16, 23, 25 and 41) of SEQ ID NO: 380 is referred as $X_{Hi}$, wherein $X_{H16}$ is E or Q, $X_{H23}$ is A or T, $X_{H25}$ is S or Y, $X_{H41}$ is H or P; and
a light chain variable region comprising SEQ ID NO: 381 (DIXMTQSPXSLXXXXGXXXXIXCKSSQSLLXSSTQKNYLAWYXQKPGX XPXLLIYFASTRDSGVPXRFSGSGSGTDFTLXISXXXXEDLXXYFCQQHYI IPFTFGQGTKLEIK), wherein the X at position i (i=3, 9, 12, 13, 14, 15, 17, 18, 19, 20, 22, 31, 43, 48, 49, 51, 66, 80, 83, 84, 85, 86, 90 and 91) of SEQ ID NO: 381 is referred as $X_{Li}$, wherein $X_{L3}$ is V or Q, $X_{L9}$ is D, L or S, $X_{L12}$ is A, S or P, $X_{L13}$ is A or V, $X_{L14}$ is S or T, $X_{L15}$ is L, V or P, $X_{L17}$ is D or E, $X_{L18}$ is R or P, $X_{L19}$ is A or V, $X_{L20}$ is S or T, $X_{L22}$ is N, T or S, $X_{L31}$ is N or Q, $X_{L43}$ is Q or L, $X_{L48}$ is Q or K, $X_{L49}$ is A, P or S, $X_{L51}$ is K or Q, $X_{L66}$ is S or D, $X_{L80}$ is K or T, $X_{L83}$ is R or S, $X_{L84}$ is L or V, $X_{L85}$ is Q or E, $X_{L86}$ is A or P, $X_{L90}$ is A or G, $X_{L91}$ is T or V.

6. The multi-specific antibody or antigen-binding fragment thereof of claim 1, wherein the first binding domain comprises:
   (i) a heavy chain variable region comprising 1, 2, or 3 CDR sequences shown as SEQ ID NO: 9, SEQ ID NO: 10 or 374 (MRNKAN**A**YTT), and SEQ ID NO: 11 or 375 (VRDR**E**GRPFAY), respectively; and a kappa light

chain variable region comprising 1, 2, or 3 CDR sequences shown as SEQ ID NO: 12 or 376 (QSLLN**A**INQKNF), SEQ ID NO: 13, and SEQ ID NO: 14, respectively; or

(ii) a heavy chain variable region comprising 1, 2, or 3 CDR sequences shown as SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, respectively; and a kappa light chain variable region comprising 1, 2, or 3 CDR sequences shown as SEQ ID NO: 44 or 377 (QSLL**Q**SSTQKNY), SEQ ID NO: 45, and SEQ ID NO: 46, respectively.

7. The multi-specific antibody or antigen-binding fragment thereof of claim 1, wherein the first binding domain comprises a heavy chain variable region comprising a sequence selected from SEQ ID NO: 351, 353, 355, 357, 358, 360, 362, 364, 365, 367 and 370; and a light chain variable region comprising a sequence selected from SEQ ID NO: 352, 354, 356, 359, 361, 363, 366, 368, 369, 371, 372 and 373.

8. The multi-specific antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the first binding domain comprises:

a) a heavy chain variable region comprising SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 8;

b) a heavy chain variable region comprising SEQ ID NO: 15 and a light chain variable region comprising SEQ ID NO: 16;

c) a heavy chain variable region comprising SEQ ID NO: 23 and a light chain variable region comprising SEQ ID NO: 24;

d) a heavy chain variable region comprising SEQ ID NO: 31 and a light chain variable region comprising SEQ ID NO: 32;

e) a heavy chain variable region comprising SEQ ID NO: 39 and a light chain variable region comprising SEQ ID NO: 40;

f) a heavy chain variable region comprising SEQ ID NO: 47 and a light chain variable region comprising SEQ ID NO: 48;

g) a heavy chain variable region comprising SEQ ID NO: 55 and a light chain variable region comprising SEQ ID NO: 56;

h) a heavy chain variable region comprising SEQ ID NO: 63 and a light chain variable region comprising SEQ ID NO: 64;

i) a heavy chain variable region comprising SEQ ID NO: 71 and a light chain variable region comprising SEQ ID NO: 72;

j) a heavy chain variable region comprising SEQ ID NO: 79 and a light chain variable region comprising SEQ ID NO: 80;

k) a heavy chain variable region comprising SEQ ID NO: 87 and a light chain variable region comprising SEQ ID NO: 88;

l) a heavy chain variable region comprising SEQ ID NO: 95 and a light chain variable region comprising SEQ ID NO: 96;

m) a heavy chain variable region comprising SEQ ID NO: 103 and a light chain variable region comprising SEQ ID NO: 104;

n) a heavy chain variable region comprising SEQ ID NO: 111 and a light chain variable region comprising SEQ ID NO: 112;

o) a heavy chain variable region comprising SEQ ID NO: 119 and a light chain variable region comprising SEQ ID NO: 120;

p) a heavy chain variable region comprising SEQ ID NO: 127 and a light chain variable region comprising SEQ ID NO: 128;

q) a heavy chain variable region comprising SEQ ID NO: 135 and a light chain variable region comprising SEQ ID NO: 136;

r) a heavy chain variable region comprising SEQ ID NO: 143 and a light chain variable region comprising SEQ ID NO: 144;

s) a heavy chain variable region comprising SEQ ID NO: 151 and a light chain variable region comprising SEQ ID NO: 152;

t) a heavy chain variable region comprising SEQ ID NO: 159 and a light chain variable region comprising SEQ ID NO: 160;

u) a heavy chain variable region comprising SEQ ID NO: 167 and a light chain variable region comprising SEQ ID NO: 168;

v) a heavy chain variable region comprising SEQ ID NO: 175 and a light chain variable region comprising SEQ ID NO: 176;

w) a heavy chain variable region comprising SEQ ID NO: 183 and a light chain variable region comprising SEQ ID NO: 184;

x) a heavy chain variable region comprising SEQ ID NO: 191 and a light chain variable region comprising SEQ ID NO: 192;

y) a heavy chain variable region comprising SEQ ID NO: 199 and a light chain variable region comprising SEQ ID NO: 200;

z) a heavy chain variable region comprising SEQ ID NO: 207 and a light chain variable region comprising SEQ ID NO: 208;

aa) a heavy chain variable region comprising SEQ ID NO: 215 and a light chain variable region comprising SEQ ID NO: 216;

bb) a heavy chain variable region comprising SEQ ID NO: 223 and a light chain variable region comprising SEQ ID NO: 224;

cc) a heavy chain variable region comprising SEQ ID NO: 231 and a light chain variable region comprising SEQ ID NO: 232;

dd) a heavy chain variable region comprising SEQ ID NO: 239 and a light chain variable region comprising SEQ ID NO: 240;

ee) a heavy chain variable region comprising SEQ ID NO: 247 and a light chain variable region comprising SEQ ID NO: 248;

ff) a heavy chain variable region comprising SEQ ID NO: 255 and a light chain variable region comprising SEQ ID NO: 256;

gg) a heavy chain variable region comprising SEQ ID NO: 263 and a light chain variable region comprising SEQ ID NO: 264;

hh) a heavy chain variable region comprising SEQ ID NO: 271 and a light chain variable region comprising SEQ ID NO: 272;

ii) a heavy chain variable region comprising SEQ ID NO: 279 and a light chain variable region comprising SEQ ID NO: 280;

jj) a heavy chain variable region comprising SEQ ID NO: 287 and a light chain variable region comprising SEQ ID NO: 288;

kk) a heavy chain variable region comprising SEQ ID NO: 295 and a light chain variable region comprising SEQ ID NO: 296;

ll) a heavy chain variable region comprising SEQ ID NO: 303 and a light chain variable region comprising SEQ ID NO: 304;

mm) a heavy chain variable region comprising SEQ ID NO: 311 and a light chain variable region comprising SEQ ID NO: 312;

nn) a heavy chain variable region comprising SEQ ID NO: 319 and a light chain variable region comprising SEQ ID NO: 320;

oo) a heavy chain variable region comprising SEQ ID NO: 327 and a light chain variable region comprising SEQ ID NO: 328;

pp) a heavy chain variable region comprising SEQ ID NO: 335 and a light chain variable region comprising SEQ ID NO:336;

qq) a heavy chain variable region comprising SEQ ID NO: 343 and a light chain variable region comprising SEQ ID NO: 344;

rr) a heavy chain variable region comprising SEQ ID NO: 347 and a light chain variable region comprising SEQ ID NO: 348; or

ss) a heavy chain variable region comprising SEQ ID NO: 349 and a light chain variable region comprising SEQ ID NO: 350.

9. The multi-specific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein:

(i) the first binding domain further comprises one or more amino acid residue substitutions or modifications yet retains specific binding affinity to human CD276,

optionally, the substitution is in one or more CDR sequences, and/or in one or more of the VH or VL sequences but not in any of the CDR sequences;

(ii) the multi-specific antibody or antigen-binding fragment further comprises an activating receptor binding domain, and, optionally, the activating receptor binding domain is a constant region of human Ig, or a constant region of

human IgG, and, optionally, the first binding domain is an intact antibody, optionally,

the constant region comprises a constant region of human IgG1, IgG2, IgG3, or IgG4; and/or

(iii) the second target is PD-L1.

10. The multi-specific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the second binding domain comprises 1, 2, or 3 heavy chain complementarity determining region (CDR) sequences selected from the group consisting of: SEQ ID NOs: 384-386, and/or 1, 2, or 3 light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 387-389; preferably the second binding domain comprises a heavy chain variable region comprising three CDR sequences set forth as SEQ ID NOs: 384, 385 and 386, respectively; and a light chain variable region comprising three CDR sequences set forth as SEQ ID NOs: 387, 388 and 389, respectively.

11. The multi-specific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the second binding domain comprises a heavy chain variable set forth as SEQ ID NO: 382, and/or a light chain variable region set forth as SEQ ID NO: 383.

12. The multi-specific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the second binding domain further comprises one or more amino acid residue substitutions or modifications yet retains specific binding affinity to human PD-L1,

optionally, the substitution is in one or more CDR sequences, and/or in one or more of the VH or VL sequences but not in any of the CDR sequences.

13. The multi-specific antibody or antigen-binding fragment thereof of claim 1, wherein the second binding domain comprising an scFv structure of VH-linker-VL, optionally,
the linker comprises a sequence of $(GGGGS)_3$ (SEQ ID NO: 390).

14. The multi-specific antibody or antigen-binding fragment thereof of any of the preceding claims, wherein:
(i) the N-termination of the second binding domain is operably linked to the C-termination of the activating receptor binding domain;
(ii) the multi-specific antibody or antigen-binding fragment thereofis a bi-specific or tri-specific antibody; and/or
(iii) the multi-specific antibody or antigen-binding fragment thereofis linked to one or more conjugates, optionally, wherein the conjugate is covalently attached either directly or via a linker,
optionally the conjugate comprises a clearance-modifying agent, a chemotherapeutic agent, a toxin, a radioactive isotope, a lanthanide, a luminescent label, a fluorescent label, an enzyme-substrate label, a DNA-alkylators, a topoisomerase inhibitor, a tubulin-binders, or other anticancer drugs.

15. A pharmaceutical composition comprising the multi-specific antibody or antigen-binding fragment thereof of any one of the preceding claims, and a pharmaceutically acceptable carrier.

16. An isolated polynucleotide encoding the multi-specific antibody or antigen-binding fragment thereof of any one of claims 1-14.

17. A vector comprising the isolated polynucleotide of claim 16.

18. A host cell comprising the vector of claim 17.

19. A method of expressing the multi-specific antibody or antigen-binding fragment thereof of any one of claims 1-14, comprising culturing the host cell of claim 18 under the condition at which the vector of claim 17 is expressed.

20. Use of the multi-specific antibody or antigen-binding fragment thereof of claims 1-14 or the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a disease or condition in a subject that would benefit from modulation of CD276 activity and/or PD-L1.

21. The use of claim 20, wherein:
the disease or condition is a CD276 and/or PD-L1 related disease or condition, or the disease or condition is cancer, adaptive immune disease, autoimmune disease, inflammatory disease, or infectious disease;
optionally wherein:
(i) the cancer is adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic

cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterior uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer, optionally, wherein the cancer is chemoresistant; or

(ii) the disease or condition is hematological cancer chosen from B-cell lymphomas, optionally Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL), Marginal zone B-cell lymphoma (MZL), Mantle cell lymphoma (MCL), Richter's syndrome, Burkitt’s lymphoma or follicular lymphoma.